Previous studies find the therapeutic effects of MSCs on APAP-induced liver failure [22–26] by inhibiting CYP2E1 activity [25], maintaining GSH levels [27] and increasing antioxidant enzyme activity [28]. The gene discussed is CYP2E1; the disease is liver failure.